Agent Orange information from Vietnam Veterans of America (VVA)
Information on Agent Orange and VA Benefits (VA)
Blue Water Navy. “The Blue Water Navy Vietnam Veterans Act of 2019 (P.L. 116-23) is the most recent action taken by Congress to grant disability compensation benefits to veterans exposed to Agent Orange, a combination of tactical herbicides used by the U.S. military in Vietnam. Earlier legislation directed the Department of Veterans Affairs (VA) to provide some veterans with VA benefits for specific disabilities without requiring proof of actual exposure to Agent Orange. …The act requires VA to grant the presumption of exposure to herbicide agents to veterans who served on U.S. Navy or Coast Guard vessels off the coast of Vietnam.” FOR MORE DETAILS SEE: Expansion of Benefits to Blue Water Navy Vietnam Veterans, Congressional Research Service, Report IF11368, November 20, 2019.
Presumptive conditions for VA service-connection claims:
| Presumptive Condition: | Authorized by: |
| Adult fibrosarcoma | 38 CFR § 3.309(e) |
| AL amyloidosis | 38 CFR § 3.309(e) |
| Alveolar soft part sarcoma | 38 CFR § 3.309(e) |
| Angiosarcoma (hemangiosarcoma and lymphangiosarcoma) | 38 CFR § 3.309(e) |
| B-cell leukemias, chronic (all, including, but not limited to, hairy-cell leukemia and chronic lymphocytic leukemia) | 38 CFR § 3.309(e) |
| Bladder cancer | 38 USC 1116(a)(2) |
| Chloracne or another acneform disease consistent with chloracne becoming manifest to a degree of disability of 10 percent or more within one year after the last date on which the veteran performed active military, naval, or air service in the Republic of Vietnam during the period beginning on January 9, 1962, and ending on May 7, 1975 | 38 USC 1116(a)(2); 38 CFR § 3.309(e) |
| Clear cell sarcoma of tendons and aponeuroses | 38 CFR § 3.309(e) |
| Congenital and infantile fibrosarcoma | 38 CFR § 3.309(e) |
| Dermatofibrosarcoma protuberans | 38 CFR § 3.309(e) |
| Diabetes Mellitus (Type 2) | 38 USC 1116(a)(2) |
| Diabetes, Type 2 (also known as Type II diabetes mellitus or adult-onset diabetes) | 38 CFR § 3.309(e) |
| Early-onset peripheral neuropathy | 38 CFR § 3.309(e) |
| Ectomesenchymoma | 38 CFR § 3.309(e) |
| Epithelioid leiomyosarcoma (malignant leiomyoblastoma) | 38 CFR § 3.309(e) |
| Epithelioid sarcoma | 38 CFR § 3.309(e) |
| Extraskeletal Ewing’s sarcoma | 38 CFR § 3.309(e) |
| Hodgkin’s disease becoming manifest to a degree of disability of 10 percent or more | 38 USC 1116(a)(2); 38 CFR § 3.309(e) |
| Hypothyroidism | 38 USC 1116(a)(2) |
| Ischemic heart disease (including, but not limited to, acute, subacute, and old myocardial infarction; atherosclerotic cardiovascular disease including coronary artery disease (including coronary spasm) and coronary bypass surgery; and stable, unstable and Prinzmetal’s angina) | 38 CFR § 3.309(e) |
| Leiomyosarcoma | 38 CFR § 3.309(e) |
| Liposarcoma | 38 CFR § 3.309(e) |
| Malignant fibrous histiocytoma | 38 CFR § 3.309(e) |
| Malignant ganglioneuroma | 38 CFR § 3.309(e) |
| Malignant giant cell tumor of tendon sheath | 38 CFR § 3.309(e) |
| Malignant glomus tumor | 38 CFR § 3.309(e) |
| Malignant granular cell tumor | 38 CFR § 3.309(e) |
| Malignant hemangiopericytoma | 38 CFR § 3.309(e) |
| Malignant mesenchymoma | 38 CFR § 3.309(e) |
| Malignant schwannoma, including malignant schwannoma with rhabdomyoblastic differentiation (malignant Triton tumor), glandular and epithelioid malignant schwannomas | 38 CFR § 3.309(e) |
| Multiple myeloma becoming manifest to a degree of disability of 10 percent or more | 38 USC 1116(a)(2); 38 CFR § 3.309(e) |
| Non-Hodgkin’s lymphoma becoming manifest to a degree of disability of 10 percent or more. | 38 USC 1116(a)(2); 38 CFR § 3.309(e) |
| Parkinson’s disease | 38 CFR § 3.309(e) |
| Parkinsonism | 38 USC 1116(a)(2) |
| Porphyria cutanea tarda becoming manifest to a degree of disability of 10 percent or more within a year after the last date on which the veteran performed active military, naval, or air service in the Republic of Vietnam during the period beginning on January 9, 1962, and ending on May 7, 1975 | 38 USC 1116(a)(2); 38 CFR § 3.309(e) |
| Proliferating (systemic) angioendotheliomatosis | 38 CFR § 3.309(e) |
| Prostate cancer | 38 CFR § 3.309(e) |
| Respiratory cancers (cancer of the lung, bronchus, larynx, or trachea) becoming manifest to a degree of disability of 10 percent or more | 38 CFR § 3.309(e) |
| Rhabdomyosarcoma | 38 CFR § 3.309(e) |
| Soft-tissue sarcoma | 38 USC 1116(a)(2) |
| soft-tissue sarcoma becoming manifest to a degree of disability of 10 percent or more other than osteosarcoma, chondrosarcoma, Kaposi’s sarcoma, or mesothelioma | 38 CFR § 3.309(e) |
| Synovial sarcoma (malignant synovioma) | 38 CFR § 3.309(e) |
